| Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma A Younes, AK Gopal, SE Smith, SM Ansell, JD Rosenblatt, KJ Savage, ... Journal of clinical oncology 30 (18), 2183-2189, 2012 | 1802 | 2012 |
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ... New England Journal of Medicine 370 (11), 1008-1018, 2014 | 1269 | 2014 |
| Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells BG Till, MC Jensen, J Wang, EY Chen, BL Wood, HA Greisman, X Qian, ... Blood, The Journal of the American Society of Hematology 112 (6), 2261-2271, 2008 | 904 | 2008 |
| Diagnosis and management of multiple myeloma: a review AJ Cowan, DJ Green, M Kwok, S Lee, DG Coffey, LA Holmberg, S Tuazon, ... Jama 327 (5), 464-477, 2022 | 711 | 2022 |
| CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results BG Till, MC Jensen, J Wang, X Qian, AK Gopal, DG Maloney, ... Blood, The Journal of the American Society of Hematology 119 (17), 3940-3950, 2012 | 698 | 2012 |
| Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute … RB Walter, TA Gooley, BL Wood, F Milano, M Fang, ML Sorror, EH Estey, ... Journal of clinical oncology 29 (9), 1190-1197, 2011 | 449 | 2011 |
| Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma R Chen, AK Gopal, SE Smith, SM Ansell, JD Rosenblatt, KJ Savage, ... Blood, The Journal of the American Society of Hematology 128 (12), 1562-1566, 2016 | 447 | 2016 |
| Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303 NL Bartlett, WH Wilson, SH Jung, ED Hsi, MJ Maurer, LD Pederson, ... Journal of clinical oncology 37 (21), 1790-1799, 2019 | 417 | 2019 |
| International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, ... Annals of Oncology 28 (7), 1436-1447, 2017 | 379 | 2017 |
| A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma A Forero‐Torres, JP Leonard, A Younes, JD Rosenblatt, P Brice, ... British journal of haematology 146 (2), 171-179, 2009 | 327 | 2009 |
| Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity CA Jacobson, BD Hunter, R Redd, SJ Rodig, PH Chen, K Wright, ... Journal of Clinical Oncology 38 (27), 3095-3106, 2020 | 306 | 2020 |
| Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma AK Gopal, R Chen, SE Smith, SM Ansell, JD Rosenblatt, KJ Savage, ... Blood, The Journal of the American Society of Hematology 125 (8), 1236-1243, 2015 | 290 | 2015 |
| High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a … AK Gopal, TA Gooley, DG Maloney, SH Petersdorf, JF Eary, JG Rajendran, ... Blood 102 (7), 2351-2357, 2003 | 262 | 2003 |
| Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer NH Segal, AR He, T Doi, R Levy, S Bhatia, MJ Pishvaian, R Cesari, ... Clinical Cancer Research 24 (8), 1816-1823, 2018 | 257 | 2018 |
| High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma AK Gopal, JG Rajendran, SH Petersdorf, DG Maloney, JF Eary, BL Wood, ... Blood, The Journal of the American Society of Hematology 99 (9), 3158-3162, 2002 | 255 | 2002 |
| Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies NL Bartlett, R Chen, MA Fanale, P Brice, A Gopal, SE Smith, R Advani, ... Journal of hematology & oncology 7, 1-8, 2014 | 225 | 2014 |
| Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation AK Gopal, R Ramchandren, OA O'Connor, RB Berryman, RH Advani, ... Blood, The Journal of the American Society of Hematology 120 (3), 560-568, 2012 | 222 | 2012 |
| Allogeneic hematopoietic cell transplantation after conditioning with 131I–anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly … JM Pagel, TA Gooley, J Rajendran, DR Fisher, WA Wilson, BM Sandmaier, ... Blood, The Journal of the American Society of Hematology 114 (27), 5444-5453, 2009 | 196 | 2009 |
| Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated … OW Press, JM Unger, LM Rimsza, JW Friedberg, M LeBlanc, ... Journal of Clinical Oncology 31 (3), 314-320, 2013 | 191 | 2013 |
| 131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission JM Pagel, FR Appelbaum, JF Eary, J Rajendran, DR Fisher, T Gooley, ... Blood 107 (5), 2184-2191, 2006 | 181 | 2006 |
